Eckert & Ziegler SE (ISIN DE0005659700, TecDAX) today signed a licence agreement with Qi Kang Medical, Ltd (QKM), a joint venture between Eckert & Ziegler ...

20251301_ITM and Ariceum Therapeutics Enter Into Supply Agreement for Therapeutic Medical Radioisotope Actinium-225 ...

Korea is set to begin domestic production of actinium-225 (Ac-225), a key raw material for next-generation cancer treatments, ...

Ariceum Therapeutics (Ariceum), a private biotech company developing radiopharmaceutical products for the diagnosis and treatment of certain hard-to-treat cancers, and ITM Isotope Technologies Munich ...

Ac-SSO110 (satoreotide) is a first in class Actinium-labelled SSTR2 receptor antagonistPhase I/II SANTANA-225 study on track to enrol patients in Q1 2025BERLIN, Jan. 14, 2025 /PRNewswire/ ...

(RTTNews) - Actinium Pharmaceuticals Inc. (ATNM) Monday announced a narrower loss for the third quarter. The September quarter loss was $11.6 million, compared to $13.3 million a year ago.

Actinium Pharmaceuticals ( (ATNM)) has released its Q3 earnings. Here is a breakdown of the information Actinium Pharmaceuticals presented to its investors. Actinium Pharmaceuticals, Inc.

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

NEW YORK (AP) — NEW YORK (AP) — Actinium Pharmaceuticals Inc. (ATNM) on Thursday reported a loss of $11.6 million in its third quarter. On a per-share basis, the New York-based company said it ...

Garching / Munich / Berlin, Germany, January 13, 2025 - ITM Isotope Technologies Munich SE(Ariceum), a private biotech company developing radiopharmaceutical products for the diagnosis and treatment o ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...